Q2 EPS Estimate for Vir Biotechnology Boosted by Analyst

Vir Biotechnology, Inc. (NASDAQ:VIR) – Research analysts at HC Wainwright lifted their Q2 2025 earnings estimates for Vir Biotechnology in a report issued on Tuesday, May 20th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.54) for the quarter, up from their prior forecast of ($0.84). HC Wainwright has a “Buy” rating and a $110.00 price objective on the stock. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($3.92) per share. HC Wainwright also issued estimates for Vir Biotechnology’s Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($2.48) EPS, Q1 2026 earnings at ($0.53) EPS, Q2 2026 earnings at ($0.55) EPS, Q3 2026 earnings at ($0.57) EPS, Q4 2026 earnings at ($0.58) EPS, FY2026 earnings at ($2.23) EPS, FY2027 earnings at ($2.28) EPS, FY2028 earnings at ($1.78) EPS and FY2029 earnings at ($1.37) EPS.

VIR has been the subject of a number of other reports. Barclays raised their price target on Vir Biotechnology from $26.00 to $31.00 and gave the company an “overweight” rating in a report on Friday, February 28th. The Goldman Sachs Group lowered their target price on Vir Biotechnology from $28.00 to $21.00 and set a “buy” rating for the company in a research note on Thursday, April 17th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $14.00 price target on shares of Vir Biotechnology in a report on Thursday. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Vir Biotechnology presently has a consensus rating of “Moderate Buy” and an average price target of $32.86.

Vir Biotechnology Trading Up 2.2%

NASDAQ VIR opened at $4.61 on Thursday. Vir Biotechnology has a 1-year low of $4.32 and a 1-year high of $14.45. The company has a 50 day moving average of $5.77 and a 200-day moving average of $7.73. The firm has a market cap of $637.28 million, a price-to-earnings ratio of -1.18 and a beta of 1.36.

Vir Biotechnology (NASDAQ:VIR) last announced its earnings results on Wednesday, May 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.05). The firm had revenue of $3.03 million for the quarter, compared to analyst estimates of $8.59 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The company’s revenue for the quarter was down 94.6% compared to the same quarter last year. During the same quarter last year, the business earned ($0.48) EPS.

Institutional Trading of Vir Biotechnology

Several institutional investors and hedge funds have recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Vir Biotechnology in the 4th quarter worth $42,000. GAMMA Investing LLC lifted its stake in Vir Biotechnology by 524.3% in the first quarter. GAMMA Investing LLC now owns 7,111 shares of the company’s stock valued at $46,000 after buying an additional 5,972 shares during the period. SBI Securities Co. Ltd. bought a new position in Vir Biotechnology during the fourth quarter worth about $60,000. PNC Financial Services Group Inc. boosted its holdings in Vir Biotechnology by 31.8% during the fourth quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company’s stock worth $61,000 after buying an additional 1,999 shares during the last quarter. Finally, KBC Group NV grew its position in shares of Vir Biotechnology by 136.5% during the 4th quarter. KBC Group NV now owns 8,970 shares of the company’s stock worth $66,000 after buying an additional 5,177 shares during the period. Institutional investors own 65.32% of the company’s stock.

Insider Buying and Selling at Vir Biotechnology

In related news, EVP Verneuil Vanina De sold 7,373 shares of the stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $9.14, for a total value of $67,389.22. Following the transaction, the executive vice president now directly owns 79,460 shares in the company, valued at $726,264.40. This represents a 8.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Backer Marianne De sold 79,712 shares of the firm’s stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $5.95, for a total transaction of $474,286.40. Following the completion of the transaction, the chief executive officer now directly owns 769,505 shares in the company, valued at approximately $4,578,554.75. The trade was a 9.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 15.60% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).